Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer

Clinical Cancer Research

Volumn 22, Issue 9, 2016, Pages 2177-2182

  Mansfield, Aaron S ^a   Murphy, Stephen J ^a   Peikert, Tobias ^a   Yi, Eunhee S ^a   Vasmatzis, George ^a   Wigle, Dennis A ^a   Aubry, Marie Christine ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN; PROGRAMMED CELL DEATH LIGAND 1; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG METASTASIS; MALE; MULTIPLE CANCER; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR CELL; IMMUNOTHERAPY; LUNG; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

AGED; B7-H1 ANTIGEN; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84968895056     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2246     Document Type: Article

References (26)

1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med 2015;373:123-35.
2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
3. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-67.
4. Arai J, Tsuchiya T, Oikawa M, Mochinaga K, Hayashi T, Yoshiura K, et al. Clinical and molecular analysis of synchronous double lung cancers. Lung cancer 2012;77:281-87.
5. Gazdar AF, Minna JD. Multifocal lung cancers-clonality vs field cancerization and does it matter? J Natl Cancer Inst 2009;101:541-43.
6. Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg 2007;134:630-37.
7. Deschamps C, Pairolero PC, Trastek VF, Payne WS. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg 1990;99: 769-777.
8. Kim TJ, Goo JM, Lee KW, Park CM, Lee HJ, et al. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung cancer 2009;64:171-78.
9. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg 2004;78:1194-99.
10. Pommier RF, Vetto JT, Lee JT, Johnston KM. Synchronous non-small cell lung cancers. Am J Surg 1996;171:521-24.
11. Verhagen AF, Tavilla G, van de Wal HJ, Cox AL, Lacquet LK, et al. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1994;42: 40-44.
12. Murphy SJ, Aubry MC, Harris FR, Halling GC, Johnson SH, Terra S, et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small cell lung cancer. J Clin Oncol 2014;32:4050-58.
13. Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009;33: 1752-64.
14. Murphy SJ, Cheville JC, Zarei S, Johnson SH, Sikkink RA, Kosari F, et al. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res 2012;19: 395-406.
15. Drucker TM, Johnson SH, Murphy SJ, Cradic KW, Therneau TM, Vasmatzis G, et al. BIMA V3: an aligner customized for mate pair library sequencing. Bioinformatics 2014;30:1627-29.
16. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012;120:2280-89.
17. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009;19:1639-45.
18. Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, et al. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res 2015;75:2928-36.
19. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
20. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-69.
21. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
22. Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH, et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung cancer 2015;88:24-33.
23. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28:245-53.
24. Kluger HM, Zito CR, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, et al. Characterization of PD-L1 Expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 2015;21:3052-60.
25. Leventakos K, Mansfield AS. Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res 2014;3:411-3.
26. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16.